Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos

Neurochemical Research

Volumn 21, Issue 3, 1996, Pages 331-337

  Hinz, Volker C ^a   Grewig, Sonja ^a   Schmidt, Bernard H ^a  

^a MEDA Manufacturing GmbH   (Germany)

Author keywords

Alzheimer's disease; blood; brain; cholinesterase inhibitors; colorimetric assay; dichlorvos; in vitro; metrifonate; physostigmine; tetrahydroaminoacridine

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DICHLORVOS; METRIFONATE; PHYSOSTIGMINE; TACRINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINESTERASE INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ANALYSIS; MALE; NEUROTOXICITY; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DICHLORVOS; HYDROGEN-ION CONCENTRATION; KINETICS; MALE; PHYSOSTIGMINE; RATS; RATS, WISTAR; TACRINE; TRICHLORFON;

ANIMALIA;

EID: 0029915565     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02531649     Document Type: Article

References (36)

1. Holmstedt, B., Nordgren, I., Sandoz, M., and Sundwall, A. 1978. Metrifonate: Summary of toxicological and pharmacological information available. Arch. Toxicol. 41:3-29.
2. Lorenz, W., Henglein, A., and Schrader, G. 1955. The new insecticide 0,0-dimethyl 2,2,2-trichloro-1-hydroxy-ethyl-phosphonate. J. Am. Chem. Soc. 77:2554-2556.
3. Lebrun, A., and Cerf, C. 1960. Note préliminaire sur la toxicité pour l'homme d'un insecticide organophosphoré (Dipterex®). Bull. Wld. Hlth. Org. 22:579-582.
4. Collerton, D. 1986. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19:1-28.
5. Becker, R. E., and Giacobini, E. 1988. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev. Res. 12:163-195.
6. Giacobini, E. 1991. The second generation of cholinesterase inhibitors: pharmacological aspects. Pages 247-262, in Becker, R. and Giacobini, E. (eds.), Cholinergic Basis for Alzheimer Therapy, Birkhauser, New York.
7. Reiner, E., Krauthacker, B., Simeon, V., and Skrinjaric-Spoliar, M. 1975. Mechanism of inhibition in vitro of mammalian acctylcholinesterase and cholinesterase in solutions of O,O-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (Trichlorphon). Biochem. Pharmacol. 24:717-722.
8. Nordgren, I., Bergstrom, M., Holmstedt, B., and Sandoz, M. 1978. Transformation and action of metrifonate. Arch. Toxicol. 41:31-41.
9. Schneider, L. S. 1993. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 43:64-79.
10. Kumar, V., and Becker, R. E. 1989. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent for Alzheimer's disease. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:478-485.
11. Suha, A., Beller, S. A., Overall, J. E., and Swann, A. C. 1985. Efficacy of oral physostigmine in primary degenerative dementia. A double blind study of response to different dose levels. Psychopharmacology 87:147-151.
12. Becker, R. E., Giacobini, E., Elble, R., Mcllhany, M., and Sherman, K. 1988. Potential pharmacotherapy of Alzheimer's disease. A comparison of various forms of physostigmine administration. Acta Neurol. Scand. Suppl. 116:19-32.
13. Siakotos, A. N., Filbert, M., and Hester, R. 1969. A specific radioisotopic assay for acetylcholinesterase and pseudocholinesterase in brain and plasma. Biochem. Med. 3:1-12.
14. Ellman, G. L., Courtney, K. D., Andres, V. Jr., and Featherstone, R. M. 1961. A new, rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:88-95.
15. Coyle, J. T., Price, D. L. and DeLong, M. R. 1983. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184-1190.
16. Giacobini, E. 1990. The cholinergic system in Alzheimer's disease. Pages 321-332, in Aquillonius, S. S. and Gillberg, P. G. (eds.), Progress in Brain Research, Elsevier, Amsterdam.
17. Giacobini, E. 1990. Cholinergic receptors in human brain: Effects of aging and Alzheimer's disease. J. Neurosci. Res. 27:548-560.
18. Bierer, L. M., Haroutunian, V., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P., and Davis, K. 1995. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:749-760.
19. Hasselmo, M. E., and Bower, J. M. 1993. Acetylcholine and memory. Trends Neurosci. 16:218-222.
20. Mohs, R. C., and Davis, K. L. 1987. The experimental pharmacology of Alzheimer's disease and related dementias. Pages 921-928, in Meltzer, H. Y. (ed.), Psychopharmacology: The third generation of progress, Raven Press, New York.
21. Giacobini, E. 1987. Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer's disease. Keio J. Med. 36:381-391.
22. Jaen, J. C., and Davis, R. E. 1993. Cholinergic therapies for Alzheimer's disease: acetykholinesterase inhibitors of current clinical interest. Curr. Opin. Invest. Drugs 2:363-377.
23. Metcalf, R. L., Fukuto, R. B., and March, R. B. 1959. Toxic action of dipterex® and DDVP in the house fly. J. Econ. Entomol. 52: 44-49.
24. Dawson, R. M. 1990. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci. Lett. 118:85-87.
25. Aldridge, W. N. 1980. Pages 115-125, in Sandier, M. (ed.), Enzyme inhibitors as drugs, Macmillan Press, London.
26. Main, A. R. 1979. Mode of action of anticholinesterases. Pharmacol. Ther. 6:579-628.
27. Galli, A., Mori, F., Gori, I., and Lucherini, M. 1992. In vitro protection of acetylcholinesterase and butyrylcholinesterase by tetrahydroaminoacridine: comparison with physostigmine. Biochem. Pharmacol. 43:2427-2433.
28. Taylor, P., and Insel, P. A. 1990. Molecular basis of drug action. Pages 103-200, in Pratt, W. B. and Taylor, P. (eds.), Principles of drug action: the basis of pharmacology, Churchill Livingston Inc., New York.
29. Green, A. L. 1983. A theoretical kinetic analysis of the protective action exerted by eserine and other carbamate anticholinesterases against poisoning by organophosphorus compounds. Biochem. Parmacol. 32:1717-1722.
30. Wu, C. S. C., and Yang, J. T. 1989. Tacrine protection of acetylcholinesterase from inactivation by diisopropylfluorophosphate: a circular dichroism study. Mol. Pharmacol. 35:85-92.
31. Patocka, J., Bajgar, J., Bielavsky, J., and Fusek, J. 1976. Kinetics of inhibition of cholinesterases by 1,2,3,4-tetrahydro-9-aminoacridine in vitro. Collection Czechoslov. Chem. Commun. 41:816-824.
32. Nishioka, T., Kitamura, K., Fujita, T., and Nakajima, M. 1976. Kinetic constants for the inhibition of acetylcholinesterase by phenyl carbamates. Pest. Biochem. Physiol. 6:320-337.
33. Friboulet, A., Rieger, F., Goudou, D., Amitai, G., and Taylor, P. 1990. Interaction of an organophosphate with a peripheral site on acetylcholinesterase. Biochemistry 29:914-920.
34. Michaelson, S., and Gray, P. J. 1991. A second site of action of soman on acetylcholinesterase. Biochem. Pharmacol. 42:2040-2043.
35. Winteringham, F. P. W., and Fowler, K. S. 1966. Substrate and dilution effects on the inhibition of acetylcholinesterases by carbamates. Biochem. J. 101:127-134.
36. Villén, T. 1990. Determination of metrifonate and dichlorvos in whole blood using gas and gas chromatography-mass spectrometry. J. Chromatography 529:309-317.